Home > Oncology > KRASG12C NSCLC benefits from lead-in sotorasib followed by atezolizumab or pembrolizumab

KRASG12C NSCLC benefits from lead-in sotorasib followed by atezolizumab or pembrolizumab

Expert
Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY
Conference
WCLC 2022
Trial
CodeBreak
Lead-in therapy in patients with advanced KRASG12C-positive non-small cell lung cancer (NSCLC) with the small molecule sotorasib that specifically and irreversibly inhibits KRASG12C, followed by immunotherapy with pembrolizumab orĀ atezolizumab, demonstrated durable clinical activity with lower rates of grade 3-4 treatment-related adverse events compared with patients who received both therapies at the same time. These data were presented by Dr Bob Li, medical oncologist and specialist in thoracic oncology at the Memorial Sloan Kettering Cancer Center, NY, at the International Association for the Study of Lung Cancer World Conference on Lung Cancer (WCLC 2022) held in Vienna Austria, August 6 - 9, 2022 [1]. Medicom contacted Dr Li about the implications of his results.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on